source
- Inhibrx reports 9.6-month median PFS for OX40 agonist combo in phase 2 head-neck cancer trialInhibrx Biosciences presented updated data from its phase‑2 HexAgon study of the hexavalent OX40 agonist INBRX‑106 combined with Merck’s Keytruda in patients with untreated metastatic or unresectab…
- Moonwalk Biosciences raises $70M to advance siRNA obesity therapyMoonwalk Biosciences announced it has secured $70 million in financing to move its obesity program into clinical testing. The funding will support development of a small interfering RNA (siRNA) th…